



Advances in Parenteral Formulations

Guest Editors:

Prof. Dr. Anna Jelińska

Department of Pharmaceutical
Chemistry, Poznan University of
Medical Sciences, 60-780 Poznan,
Poland

Dr. Maciej Stawny

Department of Pharmaceutical
Chemistry, Poznan University of
Medical Sciences, 60-780 Poznan,
Poland

Dr. Katarzyna Dettlaff

Department of Pharmaceutical
Chemistry, Poznan University of
Medical Sciences, 60-780 Poznan,
Poland

Deadline for manuscript
submissions:

20 December 2024

Message from the Guest Editors

In recent years, there has been great progress in the field of parenteral drugs. This is due to the development of pharmaceutical technology and drug analysis as a response to the emergence of clinical challenges.

The crucial issue in parenteral formulation is chemical, physical, and microbiological stability. One of the biggest problems of the technological process of such drugs is the poor solubility and permeability of most active pharmaceutical ingredients. To overcome this disadvantage, nanotechnology is used, including lipid-based, polymeric, and hybrid nanoparticles. Prolonged drug release formulations are developed, such as in situ implants and drug carriers enabling the drug to reach a critical organ or neoplastic tumor.

Other important issues related to parenteral drugs are their safety, PK/PD interactions, and drug compatibility when administered simultaneously through the same vascular access.

This Special Issue in *Pharmaceutics* is dedicated to the advantages of parenteral formulations and aims to draw together experts in the fields of pharmaceutical sciences, technology, analytical chemistry, and clinical medicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma